Lirum Therapeutics, Inc. (LRTX)

Lirum Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Net Income	2.2	2.2	1.92
Other Operating Activities	-4.44	-4.44	-2.22
Operating Cash Flow	-2.24	-2.24	-0.31
Share Issuance / Repurchase	5.84	5.84	-
Debt Issued / Paid	0.25	0.25	0.5
Other Financing Activities	-0.01	-0.01	-0.02
Financing Cash Flow	6.08	6.08	0.48
Net Cash Flow	3.83	3.83	0.17
Free Cash Flow	-2.24	-2.24	-0.31

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).